Literature DB >> 19618223

Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital.

M M L van Rijen1, J A J W Kluytmans.   

Abstract

The objective of this study was to determine the costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital during 2001 through 2006. Variable costs included costs for isolation, contact tracing, treatment of carriers and closure of wards. Fixed costs were the costs for the building of isolation rooms and the salary of one full-time infection control practitioner. To determine the benefits of the Search and Destroy policy, the transmission rate during the study period was calculated. Furthermore, the number of cases of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia prevented was estimated, as well as its associated prevented costs and patient lives. The costs of the MRSA policy were estimated to be euro 215,559 a year, which equals euro 5.54 per admission. The daily isolation costs for MRSA-suspected and -positive hospitalised patients were euro 95.59 and euro 436.62, respectively. Application of the Search and Destroy policy resulted in a transmission rate of 0.30 and was estimated to prevent 36 cases of MRSA bacteraemia per year, resulting in annual savings of euro 427,356 for the hospital and ten lives per year (95% confidence interval [CI] 8-14). In conclusion, application of the MRSA Search and Destroy policy in a hospital in a country with a low endemic MRSA incidence saves money and lives.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618223     DOI: 10.1007/s10096-009-0775-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey.

Authors:  M Vriens; H Blok; A Fluit; A Troelstra; C Van Der Werken; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-11-08       Impact factor: 3.267

Review 2.  Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives.

Authors:  M F Q Kluytmans-Vandenbergh; J A J W Kluytmans
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

3.  Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study.

Authors:  David H Wyllie; Derrick W Crook; Tim E A Peto
Journal:  BMJ       Date:  2006-06-23

4.  Increase in a Dutch hospital of methicillin-resistant Staphylococcus aureus related to animal farming.

Authors:  Miranda Maria Lucia van Rijen; Peter H Van Keulen; Jan A Kluytmans
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

5.  The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges.

Authors:  Sara E Cosgrove; Youlin Qi; Keith S Kaye; Stephan Harbarth; Adolf W Karchmer; Yehuda Carmeli
Journal:  Infect Control Hosp Epidemiol       Date:  2005-02       Impact factor: 3.254

6.  Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital.

Authors:  E Nulens; E Broex; A Ament; R H Deurenberg; E Smeets; J Scheres; F H van Tiel; B Gordts; E E Stobberingh
Journal:  J Hosp Infect       Date:  2008-03-19       Impact factor: 3.926

7.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Authors:  Sara E Cosgrove; George Sakoulas; Eli N Perencevich; Mitchell J Schwaber; Adolf W Karchmer; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2002-12-13       Impact factor: 9.079

8.  Invasive methicillin-resistant Staphylococcus aureus infections in the United States.

Authors:  R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

9.  Staphylococcus aureus bacteremia, Europe.

Authors:  Edine W Tiemersma; Dominique L Monnet; Nienke Bruinsma; Robert Skov; Jos C M Monen; Hajo Grundmann
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

10.  Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans.

Authors:  Inge van Loo; Xander Huijsdens; Edine Tiemersma; Albert de Neeling; Nienke van de Sande-Bruinsma; Desiree Beaujean; Andreas Voss; Jan Kluytmans
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

View more
  22 in total

Review 1.  Transmission rates, screening methods and costs of MRSA--a systematic literature review related to the prevalence in Germany.

Authors:  A Tübbicke; C Hübner; A Kramer; N-O Hübner; S Fleßa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-10       Impact factor: 3.267

2.  Analysis of MRSA-attributed costs of hospitalized patients in Germany.

Authors:  C Hübner; N-O Hübner; K Hopert; S Maletzki; S Flessa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-18       Impact factor: 3.267

3.  Persistence of livestock-associated methicillin-resistant Staphylococcus aureus in field workers after short-term occupational exposure to pigs and veal calves.

Authors:  Brigitte A G L van Cleef; Haitske Graveland; Anja P J Haenen; Arjen W van de Giessen; Dick Heederik; Jaap A Wagenaar; Jan A J W Kluytmans
Journal:  J Clin Microbiol       Date:  2011-01-12       Impact factor: 5.948

4.  Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA.

Authors:  Marjan W M Wassenberg; G Ardine de Wit; Ben A van Hout; Marc J M Bonten
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

5.  A rapid and high-throughput screening approach for methicillin-resistant Staphylococcus aureus based on the combination of two different real-time PCR assays.

Authors:  Roel H T Nijhuis; Noortje M van Maarseveen; Erik J van Hannen; Anton A van Zwet; Ellen M Mascini
Journal:  J Clin Microbiol       Date:  2014-05-28       Impact factor: 5.948

6.  Costs and benefits of rapid screening of methicillin-resistant Staphylococcus aureus carriage in intensive care units: a prospective multicenter study.

Authors:  Marjan Wassenberg; Jan Kluytmans; Stephanie Erdkamp; Ron Bosboom; Anton Buiting; Erika van Elzakker; Willem Melchers; Steven Thijsen; Annet Troelstra; Christina Vandenbroucke-Grauls; Caroline Visser; Andreas Voss; Petra Wolffs; Mireille Wulf; Ton van Zwet; Ardine de Wit; Marc Bonten
Journal:  Crit Care       Date:  2012-02-07       Impact factor: 9.097

7.  Persistence of livestock associated MRSA CC398 in humans is dependent on intensity of animal contact.

Authors:  Haitske Graveland; Jaap A Wagenaar; Kelly Bergs; Hans Heesterbeek; Dick Heederik
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

8.  Impact of livestock-associated MRSA in a hospital setting.

Authors:  Nienke van de Sande-Bruinsma; Maurine A Leverstein van Hall; Maria Janssen; Nynke Nagtzaam; Sander Leenders; Sabine C de Greeff; Peter M Schneeberger
Journal:  Antimicrob Resist Infect Control       Date:  2015-04-17       Impact factor: 4.887

9.  Cost comparison of MRSA screening and management - a decision tree analysis.

Authors:  Andrea Tübbicke; Claudia Hübner; Nils-Olaf Hübner; Christian Wegner; Axel Kramer; Steffen Fleßa
Journal:  BMC Health Serv Res       Date:  2012-12-01       Impact factor: 2.655

10.  Ten-year decrease of acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at a single institution: the result of a multifaceted program combining cross-transmission prevention and antimicrobial stewardship.

Authors:  Annie Chalfine; Marie-Dominique Kitzis; Yvonnick Bezie; Adel Benali; Laurence Perniceni; Jean-Claude Nguyen; Marie Françoise Dumay; Jacqueline Gonot; Gilles Rejasse; Fred Goldstein; Jean Carlet; Benoît Misset
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-18       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.